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A B S T R A C T
The signaling networks that drive the aging process, associated functional deterioration, and pathologies has
captured the scientiﬁc community's attention for decades. While many theories exist to explain the aging
process, the production of reactive oxygen species (ROS) provides a signaling link between engagement of
cellular senescence and several age-associated pathologies. Cellular senescence has evolved to restrict tumor
progression but the accompanying senescence-associated secretory phenotype (SASP) promotes pathogenic
pathways. Here, we review known biological theories of aging and how ROS mechanistically control senescence
and the aging process. We also describe the redox-regulated signaling networks controlling the SASP and its
important role in driving age-related diseases. Finally, we discuss progress in designing therapeutic strategies
that manipulate the cellular redox environment to restrict age-associated pathology.
1. Biological theories of aging
Why do we age? The answer to this perennial question has
encouraged the scientiﬁc community to pursue hypotheses that can
delineate the mechanisms behind the human body's functional decline
with age. However, despite medical advances there remain challenges
with respect to delineating controls that regulate the span of human life
and health. Elucidation of these control mechanisms may lead to
better-targeted interventions for the gamut of diseases propagated by
age. Ultimately, amelioration of age-associated pathologies and comor-
bidities would limit age-related frailty and improve the well-being of
our aging population.
Biological aging is the progressive manifestation of accumulated
cellular damage with age, and is determined by environmental or
genetic factors [1–4]. The process of aging is complex and can be
explained by a number of complimentary theories. The wear and tear
theory, proposed by August Weismann in 1882, compares organisms to
machines, suggesting that cells ‘wear out’ with time and accumulate
damage through excessive consumption of fat, sugar, or exposure to UV
radiation, leading to declines in functional eﬃciency of organs.
However, this theory disregards the ability of cells to repair damage.
The stochastic theory which is a by-product of the wear and tear theory,
postulates that aging is due to the accumulation of damage in cells
resulting from failure of wound repairing mechanisms, infections, UV
radiation, or environmental stress [5]. Evolutionary theories of aging
support the concept that speciﬁc genes implicated in longevity are
involved in the stability and maintenance of somatic cells, and are
susceptible to mutations with age. Medawar's mutation accumulation
theory links aging to natural selection, hypothesizing that there is no
selection pressure on the aging population, as there is no known
evolutionary mechanism to eliminate a population of mutations that
cause deleterious eﬀects only in aged species [6]. This suggests that
detrimental late-acting alleles may accumulate with age and exert
adverse eﬀects on survival. The antagonistic pleiotropy model suggests
that a pleiotropic gene that selectively increases ﬁtness and survival
during the early stages of life can still induce adverse late-acting eﬀects
in the population [7]. In the context of cellular aging, this could apply
to replicative senescence that suppresses tumor formation early in life,
but may promote cancer in later stages. The disposable soma theory,
put forth as an extension of the antagonistic pleiotropy model, high-
lights the balance between somatic maintenance and repair versus
reproduction and suggests that with age extensive maintenance would
be necessary as cells can accumulate multiple lesions in parallel [8,9].
The rate of living theory puts across the idea that organisms that
metabolize oxygen more rapidly have a higher energy expenditure and
typically have shorter lifespans that can be extended by caloric
restriction [10–13]. According to the cross-linking (or glycosylation)
theory of aging, cross-linked proteins or sugar moieties can bind to
DNA causing replicative damage or an age-related decline in protein
turnover that can be linked to the loss of functional proteins, further
promoting age-associated pathologies [14].
While all of the aforementioned theories have been examined and
laboriously tested, the mitochondrial free radical theory of aging, later
termed the oxidative stress theory (OST), is currently one of the most
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popular correlative theories of the aging process. OST explains aging at
the molecular level and results from failure to maintain oxidative
defenses, mitochondrial integrity, proteostasis, barrier structures, DNA
repair, telomeres, immune function, metabolic regulation, and regen-
erative capacity (Fig. 1). More than half a century ago, Gerschman
introduced that oxygen free radicals, commonly considered to be too
reactive to exist in biological systems, are generated in situ in response
to radiation and oxygen poisoning and are responsible for the
associated toxicities [15,16]. Later, Denham Harman proposed that
hydroxyl and hydroperoxyl radicals generated endogenously from
oxygen-consuming metabolic processes play crucial roles in the aging
process [17]. This hypothesis coalesced from a number of observations:
(i) indications that free radicals are produced in vivo; (ii) free radicals
cause pervasive damage to macromolecules in vitro; and (iii) the
deleterious eﬀects of exposure to irradiation and hyperoxia are
alleviated by antioxidant administration. Free radicals are highly
reactive atoms or molecules with one or more unpaired electron(s) in
their outermost shell and can be formed when oxygen interacts with
certain molecules. They can be formed endogenously by natural
biological processes, or generated upon exposure to external stimuli.
Reactive oxygen species (ROS) collectively describes a number of
reactive molecules, such as superoxide (O2
•-), hydroxyl radical (OH•),
hydroperoxyl radical (HO2
•), nitric oxide (NO•), nitrogen dioxide
(NO2
•), and peroxyl (ROO•), produced as by-products during the
mitochondrial electron transport of aerobic respiration or by oxidor-
eductase enzymes. Also, hydrogen peroxide (H2O2), ozone (O3), singlet
oxygen (1O2), hypochlorous acid (HOCl), nitrous acid (HNO2), perox-
ynitrite (ONOO–), dinitrogen trioxide (N2O3), and lipid peroxide
(LOOH), are oxidants that can easily lead to free radical reactions in
cellular systems [18]. Expanding knowledge of the mechanisms of ROS
generation, intracellular sources, antioxidant defenses, and the chem-
istry of ROS-induced oxidative damage, was critical to improve under-
standing of the homeostasis between pro-oxidants and anti-oxidants,
thereby evolving the free radical theory into the OST of aging [19,20].
The “structural damage-based” hypothesis driving this theory is that
age-associated functional losses are due to the accrual of oxidative
damage to macromolecules such as lipids, DNA, and proteins by free
radicals, and that the progressive oxidant/anti-oxidant imbalance leads
to the consequent disruption of redox-regulated signaling mechanisms.
Beckman and Ames divided this hypothesis into “strong” and “weak”
versions: The strong version proposed that oxidative damage deter-
mines life span, while the weak version correlated oxidative damage to
age-associated pathologies [21].
Although widely accepted, the OST has been severely refuted in
recent years; most criticisms try to discredit the theory pointing at
failure to increase longevity by increasing antioxidants and the
production of fewer free radicals in certain long-living species [22–
26]. Recently, a critical idea has emerged that ROS at non-toxic levels
function as signaling molecules that induce protective defenses against
age-dependent damage, and that peroxisomes may be implicated in the
regulation of aging [27]. Currently, the two major traits correlating
organismal aging and longevity to the OST of aging are considered to
focus primarily on the species-speciﬁc low mitochondrial ROS genera-
tion rates at complex I of the electron transport chain (ETC) in long-
lived animals, and low levels of fatty acid unsaturation on cellular and
mitochondrial membranes [28–30].
2. Cellular senescence
Cellular senescence, also termed replicative senescence, was ﬁrst
proposed four decades ago [31,32] and has since been proven to be a
signiﬁcant tumor constraining mechanism that halts the proliferation
of primary mammalian cells after a ﬁnite number of population
doublings [33–37] allowing the organism to antagonize the potentially
detrimental eﬀects of uncontrolled growth. Proliferation is checked by
persistently arresting cell growth at the G1- [38–42], G2- [43–45], G2/
M- [46] or S-phase of the cell cycle leading to failure of DNA
replication. So far, senescence-associated growth arrest has been
shown to depend functionally on the tumor- suppressor pathways
controlled by p16INK4a and pRB (retinoblastoma protein), as well as by
p53. Progressive telomere attrition due to persistent DNA damage
responses [47] has been attributed to be one of the clocking mechan-
isms that keeps track of the number of times a cell divides, providing an
appropriate trigger for the onset of telomere-induced senescence
through the p53 pathway [34,48–52]. ROS can induce a senescent
growth arrest in vitro, by triggering the DNA damage response (DDR)
pathway, with ATM or ATR kinases blocking progression of the cell
cycle through stabilization of p53 and transcriptional activation of the
cyclin-dependent kinase (CDK) inhibitor p21 [53]. However, in re-
sponse to persistent DNA damage, p16INK4a is activated via p38-
MAPK-mediated mitochondrial dysfunction and ROS production.
Nuclear lamin B1 downregulation triggers modiﬁcations in chromatin
methylation and induces senescence progression with the formation of
highly condensed regions of chromatin called senescence-associated
heterochromatin foci [54]. These foci are enriched in chromatin
modiﬁcations that associate with genes required for maintenance of
senescence-associated growth arrest. Senescence can also be induced
by cell-type speciﬁc stress independent of telomere shortening, result-
ing in increased expression of the tumor suppressor p16, in which case
it is termed stress-induced senescence [42,55–57]. This includes
chronic signaling by anti-proliferative cytokines that increase cellular
oxidative stress and potentiate senescence [58–60]. Oncogene-induced
senescence (OIS), characterized by aberrant DNA replication and the
associated DNA damage response, is aﬀected by activated oncogenes or
the loss of tumor-suppressor genes in healthy cells [45,61–64] and
upregulation of the CDK inhibitors p15INK4b, p16INK4a, and p21CIP1
[65]. Therapy-induced senescence (TIS) has been described in tumor
cell lines in response to induction with selective preoperative neoadju-
vant chemotherapeutics or radiation agents, and is considered crucial
to mitigate toxicity-related side eﬀects, thereby presenting a novel
therapeutic target for cancer [66,67].
3. Senescence-Associated Secretory Phenotype (SASP)
Cellular senescence is a signiﬁcant tumor constraining mechanism
that halts cellular proliferation in response to damage that occurs
during replication. However, senescent cells acquire a deleterious,
irreversible senescence-associated secretory phenotype (SASP) invol-
ving secretion of soluble factors (interleukins, chemokines, and growth
factors), degradative enzymes like matrix metalloproteases (MMPs),
and insoluble proteins/extracellular matrix (ECM) components [33,68]
that can alter tissue microenvironments and aﬀect neighboring epithe-
lial cells in a paracrine fashion to promote tumor progression
[65,69,70]. Also termed the senescence-messaging secretome (SMS)
[71], these factors promote shedding of membrane-associated proteins,
Fig. 1. Schematic representation of the oxidative stress theory of aging. The key features
of this hypothesis are that increase in oxidants and concomitant failure of antioxidant
mechanisms cause structural damage to macromolecules which accumulates with age
leading to corresponding decline or loss in function.
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degradation of signaling molecules, and/or ECM processing, thereby
disrupting normal tissue framework and function [72].
Morphologically, senescence is characterized by cellular enlargement
and ﬂattening with an accompanying increase in cell volume, increased
size of organelles including Golgi, lysosomes and nucleus, appearance
of vacuoles in the cytoplasm and ER and an increase in the number of
cytoplasmic microﬁlaments.
The senescent phenotype has been long associated with driving
organismal aging, and has recently been linked to development and
tissue repair. The SASP is primarily a persistent DDR coupled as a
positive feedback loop with the senescent stimuli ROS, prompting
telomere-dependent or –independent signaling mechanisms to facil-
itate growth arrest. The non-cell-autonomous activities mediated by
SASP serve to deplete stem and progenitor cells and demonstrate that
the heterogeneous functional networks of senescence are formed by
multiple eﬀector pathways involving highly dynamic signal ampliﬁca-
tion [73]. The SASP can also be uncoupled from the senescence-
associated cell-cycle arrest, as it exempliﬁes a perpetual state of
damage in comparison to growth arrest. SASP has been characterized
by analysis and conservation of factors between human and mouse cells
cultured under physiological oxygen conditions [74] and its occurrence
has been seen in vivo in mice and humans [75,76] and amongst diverse
proliferative cell types (ﬁbroblasts, epithelial cells, endothelial cells,
astrocytes, etc.) [76–78].
The SASP components that modulate neighboring cells can lead to
the activation of signaling cascades involved in several disease pro-
cesses. It is suﬃcient for a given tissue to be comprised of less than
20% of senescent cells to exert SASP-mediated systemic eﬀects [79].
The gamut of downstream eﬀects initiated by SASP include tumorigen-
esis (paracrine), immunomodulation (paracrine), senescence ampliﬁ-
cation (paracrine and autocrine), transformation of the tissue micro-
environment (paracrine), and perturbation of stem cell niche [80].
Continued exposure to senescent cells has been shown to potentially
promote senescence in healthy bystander ﬁbroblasts via gap junction-
mediated cell-cell contacts and processes implicating ROS [81]. While a
deluge of evidence points out to the role of ROS in inducing senescence,
Lawless et al. employed an empirical stochastic step model of replica-
tive senescence to suggest that increased mitochondrial ROS genera-
tion in senescent cells is a repercussion of SASP rather than the reverse
[82].
The proteins of the SASP component are broadly conserved,
although diﬀerences exist among cell types [76]. The contribution of
non-protein factors such as nucleotides, bradykines, prostenoids, or
ceramides to SASP's eﬀects is also relatively unexplored. The composi-
tion of the SMS may vary dynamically with time after the initiation of
senescence and partly depends on the senescence-inducing mechan-
ism. This ‘late-induced’ senescence phenomenon propagates by form-
ing cytoplasmic chromatin fragments with DNA lesions that eventually
undergo lysosome-mediated proteolysis causing overall histone loss,
thereby illustrating perpetual genomic and epigenomic remodeling in
senescence [76].
3.1. Beneﬁcial eﬀects of SASP
The SASP is fundamentally a response to genomic damage that
allows damaged cells to communicate their compromised state to
neighboring cellsand stimulates tissue repair and/or regeneration after
insult by attracting immune cells and inducing local inﬂammation.
However, it has been indicated that senescence is not consistently
followed by immune cell inﬁltration and inﬂammation [83] as observed
in highly persistent senescent cells in human melanocytic nevi. The
SASP also includes several chemokines and cytokines that activate
immune cells to speciﬁcally target and eventually clear senescent cells
from tissues [84,85]. SASP factors such as IL-6, IL-8, protease inhibitor
plasminogen activator inhibitor-1 (PAI-1), and pleiotropic protein
insulin-like growth factor binding protein-7 (IGFBP-7) are also im-
plicated in tumor suppressive growth arrest of cells [75,86,87]. The
SASP-produced MMPs also limit ﬁbrosis during wound healing [88] or
following liver injury [89,90]. Additionally, developmentally pro-
grammed and transiently-regulated senescence is established to be
vital in promoting tissue remodeling, embryogenesis and patterning
[91–93]. Finally, the deterioration of the immune system with age
coupled with the kinetics and eﬃciency of senescent-cell clearance
determines the switch of senescence from a temporal programmed
process to a persistent stochastic response. The persistent stochastic
response involves a multitude of concurrent signals that are paramount
to the progression of chronic age-related pathologies.
3.2. SASP in disease
Cellular senescence and consequently SASP factors are involved in
several acute and chronic pathological processes (Fig. 2). In a murine
model, this association was supported by the delayed onset of age-
related diseases when senescent cells were genetically ablated [94].
Considering that the SASP components diﬀer in character from
cytokines to growth factors and proteases the eﬀects they can convey
individually or more importantly collaboratively in diﬀerent tissues
may vary as well. Byun et al. have proposed that senescent cells have a
deﬁnitive role in age-associated pathologies including their ability to
modulate young cells through 1) release of inﬂammatory SASP factors
i.e. IL-1; 2) secretion of autocrine or paracrine factors that modulate
the activity of other senescent cells or disease-prone young cells (EMT
activation by IL-6 and IL-8); 3) expression of SASP receptors (IL-17);
and 4) release of anti-inﬂammatory molecules such as IL-10 [95]. The
SASP can promote distinct disease pathologies by perpetuating a pro-
inﬂammatory state and promoting cell transdiﬀerentiation. For exam-
ple, various cardiovascular risk factors including obesity, hypertension,
diabetes and atherosclerosis that compromise metabolism are asso-
ciated with an inﬂammatory state and increased cellular senescence
and SASP [96]. Vascular calciﬁcation, another risk factor for cardio-
vascular disease, is linked to a SASP-driven osteoblastic transdiﬀer-
entiation of senescent smooth muscles cells [97], while atherogenesis
Fig. 2. Schematic representation of diseases propagated by age. Cellular senescence and
the associated secretory phenotype have been implicated in initiation and progress of
several acute and chronic pathological maladies driven by age-associated inﬂammation
(inﬂammaging) and oxidative stress-mediated damage. AMD – Age-related macular
degeneration; COPD – Chronic obstructive pulmonary disease).
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has been shown to be in part mediated by the pro-inﬂammatory IL-1α
[98]. Obese individuals with type-2 diabetes show increased levels of
SASP factors IL-6, IL-8, and the chemokine MCP-1 [96]. Moreover,
both IL-6 and IL-1β are independent predictors of diabetes [96]. In
many prevalent neurodegenerative conditions including Alzheimer's
Disease, brain tissue biopsies are present with increased levels of
p16INK4a- positive astrocytes, MMP-1 and IL-6 [99,100]. Other pre-
valent pathologies which share several damaging SASP proﬁles includ-
ing IL-6, IL-8, GM-CSF, MMP-1 [101] are chronic obstructive pul-
monary disease (COPD), biliary cirrhosis and cholangitis [102], and
osteoarthritis [103].
Although cellular senescence can serve as a tumorigenic restrictive
mechanism, it can also promote tumor growth and tumor invasiveness,
through SASP-mediated regulatory eﬀects [104,105]. A known path-
way for SASP-promoted cancer metastasis is the induction of epithelial
to mesenchymal transition (EMT); a process that can have both
beneﬁcial wound healing eﬀects, and pathological ﬁbrotic and inva-
siveness-promoting ones [106]. EMT is also a crucial process that can
elicit ﬁbrosis in Crohn's disease and graft loss after kidney transplanta-
tion [107,108]. Moreover, decreased renal function due to both acute
and chronic kidney injury has also been associated with cellular
senescence and SASP [109,110].
Though the SASP signature of speciﬁc pathological processes still
remains to be elucidated, great attention is increasingly being paid to
the eﬀects of both biological and stress-induced senescence in diﬀerent
tissues. Both the beneﬁcial and deleterious eﬀects of SASP suggest a
possible use of the implicated factors as therapeutic targets for disease
control. In addition, the oxidative stress-mediated regulation of
biological aging and age-associated pathologies has become a promis-
ing target for therapeutic strategies against age-associated maladies.
Here, we review the recent progress in understanding the role of the
oxidative stress and the cellular redox environment in senescence, with
a focus on redox-control of senescence-regulatory factors. The eﬀects of
oxidative stress on cellular senescence at a cellular and nuclear level are
depicted in Figs. 3 and 4 respectively (Figs. 3 and 4).
4. Redox Control of SASP and Age-Related Pathologies
4.1. Mammalian target of rapamycin pathway
The mammalian target of rapamycin (mTOR) protein is a highly
conserved large protein kinase of the phosphatidylinosital 3 kinase-
related kinase (PI3KK) family, and an intracellular target of rapamycin,
a pharmacological immunosuppressant approved by FDA (Food and
Drug Administration, USA) in therapies against various types of
cancers [111,112]. The conserved TOR complexes, mTORC1 and
mTORC2, can be diﬀerentiated by their distinct associated proteins,
Raptor and Rictor, respectively. mTOR complexes play crucial roles in
mediating nutrient signaling, autophagy and growth regulation
(mTORC1) and also regulate cell survival and spatial organization of
the cytoskeleton (mTOR2) [113,114].
Inhibition of mTORC1 by rapamycin may both counter damage-
inducing senescence mechanisms and enhance repair pathways, and as
a consequence, result in extended lifespan in model organisms [115].
Over the past decade, the impact of mTOR signaling on cellular aging
has gained traction with several studies performed in multiple cellular
systems that argue for a pivotal role of mTOR in the senescent program
[112,116]; however, little is known with respect to how cellular redox
state contributes to mTOR regulatory function in senescence.
Cellular stresses, such as hypoxia, or low energy status, which can
be sensed by the AMP-sensitive kinase (AMPK) inhibit mTOR signaling
[111]. Conversely, elevated mTOR activity in response to excess
nutrients leads to increased oxidative stress by enhancing mitochon-
drial oxygen consumption. Cysteine oxidation enhances phosphoryla-
tion of S6K, which is a direct readout of mTORC1 activation [117].
Conversely, treatment with reducing agents eﬀectively suppresses
mTORC1 activation via inhibition of S6K phosphorylation.
Furthermore, oxidants destabilize the mTOR-Raptor interaction but
not the mTOR-Rictor interaction suggesting that a redox-sensitive
mechanism may underlie amino acid-dependent mTORC1, but not
mTORC2 regulation [118]. These studies also indicate that the
phosphorylation of tuberous sclerosis complex (TSC2) tumor suppres-
sor protein regulates Rheb GTPase activity which plays an essential role
in mTORC1 regulation in response to cellular redox potential. GRp58
(also known as ERp57), a widely expressed protein disulﬁde isomerase
Fig. 3. Schematic representation of the redox-control of pro-aging mechanisms.
Oxidative stress-mediated regulation of several factors and mechanistic pathways plays
a critical role in senescence regulation. Several of these components can interact with
each other to induce eﬀects of the senescent phenotype. AP‐1 – Activator protein 1;
Ca2+– Calcium; FOXO – Forkhead box O; IGF-1 – Insulin-like growth factor-1; IL –
Interleukin; MMP – Matrix metalloproteinase; mTORC – Mammalian target of
rapamycin complex; NF-κB – Nuclear factor kappa-light-chain-enhancer of activated B
cells; PI3K – Phosphoinositide 3-kinase; Pot-1 – Protection of telomeres protein 1; pRb
– Retinoblastoma protein; ROS – Reactive oxygen species; SIRT – Sirtuin; SOD2 –
Superoxide dismutase 2, mitochondrial; Trf – Telomeric repeat binding factor.
Fig. 4. Schematic representation of the redox-control of pro-aging mechanisms in the
nucleus. Oxidative stress-mediated regulation of nuclear proteins can happen via
expression of factors induced by DNA damage-mediated responses or at the transcrip-
tional/translational level via modulation of protein activity, thereby allowing for precise
control over senescence eﬀector mechanisms. AP-1 – Activator protein 1; FOXO –
Forkhead box O; IL – Interleukin; NF-κB – Nuclear factor kappa-light-chain-enhancer of
activated B cells; Pot-1 – Protection of telomeres protein 1; pRb – Retinoblastoma
protein; SIRT – Sirtuin; Trf – Telomeric repeat binding factor.
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regulating protein-protein interactions through a redox-based mechan-
ism acts via its two thioredoxin-like domains and has shown to be an
mTOR-interacting protein [119]. These ﬁndings suggest that a redox-
sensitive mechanism regulates the activity of mTORC1, and the
interaction between Raptor and proteins with redox-sensing abilities
are potentially involved in the assembly and regulation of mTOR
complexes. In contrast, Liu et al. demonstrated that mTOR regulation
under hypoxic conditions is independent of cellular redox change [120]
as H2O2-scavenging by catalase failed to attenuate the hypoxic hypo-
phosphorylation of p70S6K and 4EBP1. More recently, regulation of
the mTORC2 complex formation and stability has been demonstrated
to be redox sensitive [121], as knockdown of p22phox inhibits NADPH-
dependent superoxide generation and decreases downstream Rictor-
associated mTORC2 complex activity without aﬀecting Raptor-asso-
ciated mTORC1 complex. This likely occurs through redox-control of
Rictor expression and its subsequent interaction with mTORC2.
mTORC1 also regulates mRNA translation and protein synthesis under
conditions that favor growth, and there is evidence to suggest that
regulation of mRNA translation can modulate longevity in several
model organisms [122]. The cellular redox status may likely play a role
in global reduction in mRNA translation through TOR signaling and
would be advantageous to the aging process allowing for better
maintenance of protein homeostasis. Taken together, these observa-
tions indicate that approaches that exploit the redox-sensitive nature of
both mTOR complexes might prove useful in the design of therapeutics
that target age-associated disorders.
4.2. IL-1alpha
Pro-inﬂammatory members of the interleukin-1 (IL-1) family of
cytokines (IL-1α and β) are important mediators of the host defense
response to infection, but can also aggravate inﬂammation that is
central to the progression of many disease processes [123]. IL-1α, one
of the upstream regulators of SASP, is a dual-function cytokine which is
rapidly expressed not only upon stimulation but is present constitu-
tively in healthy cells. It is synthesized as a precursor protein that is
subsequently cleaved into two functional fragments that have distinct
subcellular localizations by proteases such as calpain [124], CTL/NK-
granzyme-B, mast cell chymase, or neutrophil elastase [125]. However,
IL-1α cleavage by calpain is rare and only serves to increase the
potency of the mature form of the protein in activating pro-inﬂamma-
tory mediators of SASP.
Basal and tumor necrosis factor (TNF)-induced expression of IL-1α
has been shown to be regulated by superoxide via modulation of
mitochondrial superoxide dismutase (SOD2) that in turn inﬂuences the
cellular redox homeostasis [126]. Their ﬁndings indicate a critical role
for a superoxide-reactive intermediate of mitochondrial origin in
regulating IL-1α mRNA stability both constitutively and in response
to TNF. The IL‐1α proximal promoter contains binding sites for the
transcription factor AP-1 [127], that has previously been established to
be activated by an H2O2-dependent mechanism [128], again suggesting
the redox-dependency of IL-1α induction. In exploration of the
mechanistic drivers of IL-1α, redox-engineered ﬁbrosarcoma cells were
used to demonstrate that the cellular redox state mediates IL-1α
expression and processing through the Ca2+ dependent protease
calpain and alterations in calcium (Ca2+) homeostasis [129]. Steady
state levels of intracellular hydrogen peroxide (H2O2) signiﬁcantly
promoted IL-1α expression and nuclear translocation, where it serves
as a pro-inﬂammatory mediator by increasing NF-κB activity, thereby
further delineating the role of IL-1α in ROS-mediated inﬂammation.
Similarly, in serially cultured senescent human fetal lung ﬁbroblasts,
the redox-dependent processing of IL-1α by calpain has been shown to
be critical to the regulation of SASP [70]. Senescence-associated
upregulation of the mature form of IL-1α promoted metastatic
progression of neighboring healthy epithelial cells, triggering an
epithelial-mesenchymal transition and was reversed by antioxidant
treatment, implying a redox-driven control mechanism. More recently,
Laberge et al. have shown that mTOR drives the SASP and that
treatment with the mTOR inhibitor rapamycin partly suppresses the
secretory phenotype and tumor-promoting ability via translational
inhibition of IL-1α [130]. Despite its role in the regulation and
ampliﬁcation of SASP, there exist few studies that describe aberrant
activation mechanisms for IL-1α, thus understanding these mechan-
istic controls is necessary to allow successful therapeutic intervention
to reduce the deleterious eﬀects of the normal aging process.
4.3. Matrix metalloproteinase regulation
Matrix metalloproteinases (MMPs) are a group of endopeptidases
with important roles in wound healing, tissue remodeling and cellular
growth [131,132]. Abnormally high MMP expression is associated with
age-related and chronic diseases such as cancer, Alzheimer's, athero-
sclerosis, osteoarthritis, and lung emphysema [132]. The mitochon-
drial redox control of MMPs has been previously reported, where ROS
are shown as key regulators of MMPs including MMP-1, −2, −7, and
−9, [133–135] while also being upregulated by high levels of MMP-2
[136]. In particular, the association between MMP-1 and ROS and the
signiﬁcance of these interactions in degenerative disease etiology is well
established. MMP-1, cleaves the structural connective tissue compo-
nents collagen type I, II and II, and is detected only at low levels under
physiological conditions, but can be abnormally high in several age-
associated pathologies [132,137]. The increased expression of MMP-1
can be both age- and ROS-dependent [128,138,132]. ROS and age
associated MMP-1 expression involves the recruitment of the primary
transcription factors Ets-1/AP-1 (c-Jun/c-Fos) to the distal promoter
region of MMP-1, along with the diﬀerential recruitment of chromatin-
modifying proteins P/CAF and HDAC2. These coordinated events
mediated by ROS are responsible for induction of an active MMP-1
promoter complex. Multiple studies also show that while oxidants such
as H2O2, and antioxidant inhibitors such as aminotriazole can enhance
MMP expression [139], treatment with antioxidant agents such as
catalase, Vitamin A, Vitamin E, trans retinoic acid, resveratrol, and N-
acetyl cysteine can block or decrease MMP expression in diﬀerent cell
lines [140–146]. More recently, ROS-activated MMPs in the wall of
cerebral vessels has also been shown to be exacerbated with age in a
mouse model that recapitulates cerebromicrovascular alterations pre-
sent in elderly humans [147], adding to the growing body of literature
supporting age-associated redox-driven MMP induction. This redox
sensitive regulation of MMPs provides a deﬁnitive rationale for the use
of antioxidant-based therapies in the treatment of degenerative dis-
orders associated with aberrant matrix destruction propagated by age.
4.4. IGF Signaling and FOXO regulation
The insulin/insulin-like growth factor-1 (IGF-1) signal transduc-
tion pathway controls various proliferative, survival and metabolic
signaling networks. IGF-1 in association with its downstream eﬀectors
was the ﬁrst evolutionarily conserved longevity regulatory network
identiﬁed from yeast to humans [148,149]. Impaired insulin/IGF-1
signaling lowers the oxidative burden and the associated oxidative
damage in cells which contributes to increased longevity [150–152].
Forkhead box O (FOXO) transcription factor family members
(FOXO1, FOXO3a, FOXO4, and FOXO6 in mammals; DAF-16 in C.
elegans; DFOXO in D. melanogaster) are evolutionarily conserved
AKT substrates that regulate genes involved in cell cycle, apoptosis,
DDR, metabolism, oxidative stress defense mechanisms, and aging
[153]. The activity of FOXO proteins is primarily regulated by signaling
in response to IGF receptor engagement in a redox-dependent fashion
[154]. FOXO family members also confer protection from oxidative
stress through transcription of antioxidant genes, SOD2, catalase,
peroxiredoxin 3, and members of the sestrin family [155–157]. The
ROS-induced formation of cysteine-thiol disulﬁde-dependent com-
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plexes of FOXO with the p300/CBP (CREB-binding protein) acetyl-
transferase has also been implicated in the modulation of biological
activity of FOXO4 [158]. Overall, FOXOs serve as stress sensors and
appear to inﬂuence both pro- (inducing senescence and apoptosis) and
anti-aging (ROS scavenging) mechanisms.
Senescent endothelial, epithelial, and ﬁbroblast cells demonstrate
high expression levels of IGF-binding proteins (IGFBPs) including
IGFBP-2, −3, −4, −5, and −6 [72,159–161], and their regulating
proteins (IGFBP-rPs) IGFBP-rP1, and 2 [162,163]. IGFBP-rP1 pro-
motes senescence in part through p21 and independent of p53 [164].
Recently, IGFBP7, a potential tumor suppressor, has been identiﬁed as
a marker of oncogenic BRAF-induced senescence, via negative feed-
back loops [87,165]. The initial response to the insulin receptor
activation is the NADPH oxidase-dependent generation of H2O2
[166] that plays both positive and negative autoregulatory roles in
the regulation of insulin/IGF-1 signaling. The endogenous production
of H2O2 is implicated in the autophosphorylation of the insulin
receptor β-subunit (IRβ) tyrosine motif [167,168]·H2O2-dependent
priming of IRβ and associated proteins, coupled with reversible
oxidative inhibition of protein tyrosine phosphatases, enables IRβ
phosphorylation and sustains insulin/IGF-1 signaling.
The insulin/IGF-1 pathway turns from a growth-promoting reg-
ulator in early stages and into a senescence-inducing pathway during
the later stages of life [169,170]. A detailed characterization of the
regulatory role of ROS in insulin/IGF-1-mediated signaling at all stages
in life is crucial to design therapeutics targeting age-related disorders.
4.5. Calcium (Ca2+)
Calcium is a ubiquitous secondary signaling molecule regulating a
disparate range of physiological process, including muscle contraction,
gene transcription, and cell proliferation [171]. Comprehensive reviews
by Ureshino et al., and Farfariello et al. summarize the Ca2+ signaling
networks that may mediate senescence via multiple regulatory path-
ways including proliferation and cell cycle arrest, apoptosis, autophagy,
alterations in membrane potential, altered telomerase activity, and
SASP [172,173]. The role of Ca2+ as a key signaling intermediate
involved in SASP regulation has only recently emerged [70].
Ca2+ signaling is central to driving morphological changes that are
the hallmarks of senescence. Senescence-associated increase in cell
volume is normally countered by regulatory volume decrease (RVD)
which preserves the structural integrity of the cell [174]. Senescence-
associated cell volume changes lead to membrane stretching or osmotic
swelling-based activation of TRP vanilloid 4 (TRPV4) or TRP mela-
statin 7 (TRPM7) channels that mediate Ca2+ inﬂux from the extra-
cellular space, subsequently activating RVD counter-regulatory signals
[175,176]. Mitochondrial Ca2+ importers maintain homeostatic regula-
tion of the electron transport and increased Ca2+ inﬂux decreases
overall ATP production, elevating cytosolic NADH, decreasing sirtuin
activity leading to senescence [177]. Similarily, recent work by Wiel
et al., identiﬁed two calcium channels, inositol 1,4,5-trisphosphate
receptor, type 2 (ITPR2) localized in the ER and the mitochondrial
calcium uniporter (MCU), as novel regulators of senescence program
by increasing Ca2+ uptake [178].
In aged human fetal lung ﬁbroblasts, senescence-associated in-
creases in basal intracellular Ca2+ is implicated in downstream activa-
tion of the Ca2+-dependent protease calpain, and the subsequent
regulation of IL-1α [70]. Treatment of senescent ﬁbroblasts with
BAPTA-AM, a Ca2+chelator or calpain inhibition reduces the senes-
cence-associated expression of IL-8 and IL-6, respectively. These
observations suggest there exists both a redox and Ca2+-dependent
process in the regulation of the prominent SASP factors IL-6 and IL-8.
During OIS and replicative senescence, ITPR2 triggers Ca2+ release
from the endoplasmic reticulum (ER), with subsequent mitochondrial
Ca2+ accumulation via MCU channel, leading to reduced mitochondrial
membrane potential, ROS accumulation, and senescence. Conversely,
intracellular Ca2+ reservoirs in the mitochondria are released in
response to stress, and facilitate activation of cAMP-responsive ele-
ment binding protein 1 (CREB) that upregulates p21CIP1/WAF1 expres-
sion, thereby inhibiting cell proliferation [179]. Sharov et al. have
shown that age-dependent loss in approximately 2.8 mol of cysteine
/mol of sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCA) as a result
of oxidation, may in part be responsible for the age-dependent decline
in SERCA activity by about 40% [180]. In a similar model employing
young (5 month old) and aged (21 month old) transgenic mice,
myocyte‐speciﬁc catalase overexpression limited oxidative modiﬁcation
of SERCA and preserved SR Ca2+, SERCA activity and myocyte
relaxation [181]. The ability of catalase overexpression to preserve
SERCA activity strongly suggests that the post-translational modiﬁca-
tions of SERCA in the senescent heart are H2O2-dependent. Though the
role of Ca2+ dysregulation in physiological and organ-speciﬁc aging
processes has been explored, further work is needed to decipher the
connection between Ca2+ dynamics and oxidative damage-induced
senescence.
4.6. Sirtuins
Silent information regulator (Sir2) genes and their functional
orthologs are conserved from bacteria to humans and constitute a
family of NAD+-dependent protein histone deacetylases (HDACs)
called sirtuins (SIRT). Initially described as gene silencers, sirtuins
are implicated in a wide variety of physiological processes including
apoptosis, lipid metabolism, cellular response to stress, mitochondrial
biogenesis, fatty acid oxidation, insulin production, and inﬂammation.
SIRT regulates the lifespan-extending eﬀects of caloric restriction
improved glucose tolerance, inhibit of degenerative disorders, improve
endothelial function, promote regression of atherosclerotic plaques and
prevent cancer [182]. The sirtuins class III family is comprised of seven
human sirtuins (SIRT1-7) that exhibit deacetylation, demyristoylase,
ADP-ribosylation, lipoamidase, demalonylation, desuccinylation, or
deglutarylation activity depending on the substrate. SIRT 1–7 are
localized in various sub-cellular compartments in mammalian cells:
SIRT1, 6, and 7 are localized mainly in the nucleus [183–185], SIRT2
in the cytoplasm [186], SIRT3, 4, and 5 are active in the mitochondria
[187]. As sirtuin activity requires NAD+ as a cofactor, cellular redox
status-based NAD+/NADH ratio can further aﬀect sirtuins [188] at the
transcriptional or post-transcriptional level of activity [189,190].
Recent work has established a role for some sirtuins in cellular
senescence.
SIRT1 is the most widely studied and well-characterized sirtuin
family member and is involved in the regulation of DNA repair and
apoptosis, mitochondrial biogenesis, glucose and insulin homeostasis,
and cell stress responses. However, our knowledge pertaining to the
molecular redox control of SIRT1 is limited. A pro-oxidative shift in the
cellular environment has been shown to induce SIRT1 expression in
neural progenitors both in vitro and in vivo [191]. Additionally, the
SIRT1 promoter is directly trans-activated by hypoxia-inducible factor
(HIF) transcription factors in response to a hypoxic environment
[192]. SIRT1-mediated protection against oxidative stress-induced
cellular damage involves induction of SOD2 expression via deacetyla-
tion and modulation of FOXOs, p53, p21, and proteins involved in
DNA damage and repair in distinct cell types [193–195]. This ﬁts well
with the observation that oxidative stress promotes acetylation of p53
by removing the inhibitory eﬀect of SIRT1 on p53, activating the
downstream target p21, and inducing premature senescence followed
by pro-tumorigenic IL-6 overexpression [196]. A similar trend is
observed in the interaction of SIRT1 with RelA/p65 protein in the
NF-κB complex which deacetylates lysine 310 and potentiates the
transactivation capacity of the NF-κB complex [197]. Exposure to
cigarette smoke oxidatively decreases SIRT1 levels and concomitantly
increases NF-κB-dependent release of pro-inﬂammatory mediators in
MonoMac6 cells and in mouse lungs [198,199]. The role of SIRT1-
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FOXO3 axis in cellular adaptation to hypoxia-associated oxidative
stress has also been elucidated by Kume et al. who demonstrate that
hypoxia inhibits SIRT1 activity and prevents nuclear translocation of
FOXO3, subsequent autophagy, and cell cycle arrest leading to an
increase in mitochondrial oxidative damage in kidneys of aged mice
[200]. Interestingly, there are ambiguities in the eﬀect of SIRT1 on
FOXO activity with variations according to gene or function; SIRT
increases transcription of genes involved in cell cycle arrest and
resistance to oxidative stress and represses genes promoting FOXO-
dependent cell death [201]. Similar to the studies described above,
ionizing radiation-induced ROS also promotes cellular senescence in
articular chondrocytes by negative post-translational regulation of
SIRT1 through the ROS-dependent activation of p38 [202]. In contrast,
SIRT1 has been implicated in promoting oxidative stress through IRS-
2/Ras/ERK signaling downstream of insulin/IGF-1 receptors [203].
There also is a strong link between the insulin/IGF-1 longevity pathway
and SIRT1 activity in senescence. The IGF-1/SIRT1/p53 interplay
involves prolonged IGF-1 treatment which inhibits SIRT1 deacetylase
activity, resulting in increased p53 acetylation, stabilization, and
activation leading to premature cellular senescence [204]. Ectopic
expression of SIRT1 eﬀectively abrogates IGF-1-induced cellular
senescence, thereby linking IGF-1-SIRT1-p53 to cellular senescence.
Recently, SIRT1 has also been shown to dissociate chromatin structure
and epigenetically repress the expression of SASP factors IL-6 and IL-8
[205]. However, oxidative stress or DNA damage-mediated can dis-
sociate SIRT1 from the promoter regions of IL-6 and IL-8 increasing
their levels systemically and further expanding senescent cell popula-
tions. The RNA-binding protein HuR has been shown to stabilize
SIRT1 mRNA by binding its 3′ untranslated region in a manner that is
inhibited by redox-dependent post-translational modiﬁcations. Overall,
alterations in SIRT1 activity in response to oxidative stress appear to
promote genomic instability, enhance inﬂammation and senescence
and oﬀers an additional target for therapeutics that limit the process of
senescence.
SIRT3 acts as a tumor suppressor gene, owing to its deacetylation
role which enhances the activity of two signiﬁcant targets, SOD2 and
isocitrate dehydrogenase 2 (IDH2), the latter of which generates
NADPH for the glutathione pathway of ROS detoxiﬁcation [206–
208]. SIRT3 is also essential for the caloric restriction-mediated
mitigation of oxidative damage by regulating the glutathione antiox-
idant system, thereby regulating senescence-associated pathologies
propagated by oxidative stress [209]. Lack of SIRT3 leads to activation
of Akt signaling suggesting a potential role in increasing cellular ROS
levels and as a driver of senescence, by aﬀecting mitochondrial function
and ATP generation, ROS detoxiﬁcation, and the mitochondrial
unfolded protein response (UPR). Both SIRT3 transcript and protein
levels are induced by the generation of mitochondrial ROS [210]. In
mice fed with high fat diets for a prolonged 12-week period, evidence of
hepatic redox stress, and an associated reduction in SIRT3 transcript
and protein levels has been established [211]. SIRT3 is involved in
cancer progression, neurodegenerative and cardiovascular disease as
well as metabolic syndromes [212], and is likely a critical participant in
many age-related disease processes.
SIRT6 is another key member of the sirtuin family with varied
functions in DNA damage repair, maintenance of genomic stability,
inﬂammation, tumor suppression and participates in longevity regula-
tion [213]. The promise of employing targeting strategies against
SIRT6 for limiting age-associated disease processes by impeding
cellular senescence and delaying premature aging [214] or through
apoptosis engagement has been established [215]. Recently, Pan et al.
demonstrated that SIRT6 deﬁciency in human adult stem cells
promotes premature and accelerated cellular senescence and is accom-
panied by elevated ROS, disrupted redox homeostasis, and increased
sensitivity to oxidative stress. SIRT6 complexes with and transcrip-
tionally coactivates nuclear factor erythroid 2-related factor 2 (NRF2),
a critical regulator of antioxidant responses, thereby modulating stem
cell redox homeostasis, providing a unique target for constraining this
senescence-associated oxidative-stress based stem cell attrition [216].
The best-known actions of SIRT6 as a tumor-suppressing protein
include its inhibitory eﬀects on c-Jun by blocking IGF-Akt signaling,
and Myc, while suppression of chronic inﬂammation is achieved by
repressing TNF-α and NF-κB activity [217], thus enabling varying
levels of senescence enforcement.
4.7. Telomere maintenance
The ends of linear eukaryotic chromosomes are protected from
damage by the inclusion of tandemly repeated DNA sequences and
specialized proteins, called telomeres. In mammalian species, the
telomeric sequence TTAGGG extends in a 5’ to 3’ direction with a T-
loop structure at the end comprised of a G-rich 3’ overhang and
associated proteins that oﬀers telomeric protection. The repeats and
the bound proteins form a complex structure called sheltrin, that
camouﬂage chromosomal ends from being recognized as damaged
subsequently preventing DNA end-joining, recombination, and repair
processes. Over the course of cell division, chromosomal attrition
occurs, as the 5’ to 3’ nature of the DNA replication machinery results
in incomplete replication of the lagging parent strand. In eukaryotes,
this is resolved by the DNA polymerase enzyme telomerase, which adds
telomeric repeat sequences to the ends of chromosomes de novo and
compensates for their erosion. Telomere-associated proteins may also
localize to other sub-nuclear or sub-cellular sites, and interact with
other associated proteins to regulate telomere length [218].
Senescence is usually triggered when the terminal restriction
fragment of telomeres shorten from an average length of 15–20 kb to
4–7 kb, by contributing to a persistent DDR that propagates and
maintains senescence-associated proliferation arrest, with dysfunc-
tional telomeres, and damaged nuclear foci termed DNA segments
with chromatin alterations reinforcing senescence (DNA-SCARS)
[219]. While telomere attrition has mostly been attributed to senes-
cence induction, certain studies suggest that DNA damage, and the
ensuing damage to telomere structure may be suﬃcient to trigger
senescence independent of telomere shortening [220,221]. Also, the
complex molecular T-loop structure at the tips of telomeres that are
modulated diﬀerently in diﬀerent cell populations, may also actively
determine the cellular proliferative capacity, independent of telomere
length.
Comprehensive evidence establishes the theory that progressive
telomere loss contributes to replicative cellular senescence and is an
indicator of age-related disease. Telomere maintenance is regulated by
genetic factors and is additively determined by telomerase activity, cell
turnover rate, and stress-inducing non-genetic environmental ele-
ments. The G-rich composition of telomeres renders them highly
susceptible to oxidative damage with the formation of oxidative
damage lesions 8-oxo-2'-deoxyguanosine (8-oxo dG) [47,222] which
can induce telomere uncapping in a cell cycle-dependent manner by
titrating out essential factors such as protection of telomeres protein 1
(POT1). POT1 protects against cellular senescence by promoting
telomere elongation, 3′ overhang protection and inhibits chromosomal
aberrations [223]. Telomeric DNA is defective in the repair of oxidant-
induced single-strand breaks, therefore telomere shortening resulting
from unrepaired or residual oxidative damage determines the occur-
rence of mutations, and unrepaired nucleotides that interfere with the
replication fork [53]. This persistent stress-induced telomeric damage
is characteristically independent of telomerase activity and telomere
length. The repair deﬁciency in telomeres can be attributed to the
binding of telomeric repeat binding factor 2 (TRF2) that makes the
strand breaks inaccessible to DNA repair enzymes [224], inhibits ATM
kinase phosphorylation [225], and interacts with polymerase β [226],
thereby negatively impacting DNA repair. This also suggests that
telomere-driven senescence occurs as a potential tumor-suppression
mechanism in response to accumulating genomic damage, and not
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after a set number of cellular divisions as clocked by telomeres.
Mechanistically, telomeric foci contain multiple DDR factors signaling
through ATM to p53, up-regulating p21 and causing cell cycle arrest at
the G1 phase. Telomere- and DNA damage-independent up-regulation
of p16 was also observed, suggesting that distinctive senescence
eﬀector pathways are not mutually exclusive and can develop in
parallel, resulting in a mixed cell population, or an individual cell
responding to collective signals [42].
Recently, analysis of 3D chromosomal architecture using combined
biochemical, cytological, and computational techniques has revealed
signiﬁcant decreases in volume, and increases in chromosome compac-
tion during cellular senescence [227]. This unique senescent chromo-
somal signature is attributed to an increase in short-range chromatin
contacts and genome-wide contraction of chromosome arms. It is
hypothesized that the structural 3D organization of chromosomes may
regulate senescence-associated cell cycle arrest. Mathematical models
have been employed to quantitatively predict the role of telomere
shortening in senescence. One such model assessed rates of telomere
loss occurring from oxidative damage and activity of C-strand speciﬁc
exonuclease, and the possible interactions between these two mechan-
isms [228]. The model predicts that under lower oxidative burden the
end-replication problem and C-strand processing are major contribu-
tors to telomere loss; however under normoxic or hyperoxic conditions,
it is predicted that single strand breaks induce shortening. Another
model incorporates a shortening factor and autonomous telomere loss
and assumes that senescence incidence is proportional to telomere
length [229]. A simple negative feedback regulation model of telomere
reduction is proposed, suggesting that telomere erosion is dependent
on telomere length.
Ectopic expression of telomerase alone [230], or in combination
with p16INK4A/pRb inactivation [231] can also prevent telomeric loss-
dependent senescence in primary ﬁbroblasts and extend replicative
lifespan. Likewise, studies suggests that loss of telomeres correlates
with depletion of antioxidant enzyme levels and decreases in oxidative
burden by antioxidant treatment might limit the telomere shortening
rates and delay cellular senescence. However, a critical review and
meta-analysis on human data performed by Simons reveals no causal
involvement of telomere length in the aging process, suggesting that
thorough investigation of the mechanistic in vivo role of telomeres is
crucial to assess their function in senescence [232].
4.8. Tumor suppressors p53, p21, p16
The G1 phase of the cell cycle is the main checkpoint at which DDR
pathways activate cellular senescence as a protective mechanism to
induce cell cycle arrest. [38,233]. Both the p16INK4a/pRB and p53/p21
tumor suppressor pathways induce cell growth arrest through senes-
cence activation [234,235]. Both p16 and p53 display compensatory
interactions [236,237] and both have a role in senescence initiation
and maintenance [79,238,239].
p21 and p16 are cyclin-dependent kinase inhibitors involved in
preventing cell cycle progression by preventing pRB phosphorylation
[37,240]. In general terms, DNA damage activates DDR, a p53/21-
dependent response that is originally transient but which can become
persistent if the damage is severe enough, and which can also be
reversed through the p16/pRB pathways [219,241]. After DDR activa-
tion, the p53/p21 pathway deactivates the cyclin E-CDK2 complex
responsible for pRB phosphorylation [242], while the p16/pRB path-
way inhibits pRB phosphorylation by deactivation of kinase CDK4/6
[239]. Preventing pRB phosphorylation allows pRB to retain its
association with the transcription factor E2F1, preventing the expres-
sion of E2F1 target genes that are necessary for the cell transition from
G1 to the S phase [239].
p53 has been shown to both promote and inhibit cellular senes-
cence [243,244] partly through its up and down regulation of ROS, and
its eﬀects on mTOR. Also, a positive feedback loop between p53 and
ROS has been shown to promote senescence in human ﬁbroblasts – a
loop that can be counteracted by the cell cycle mediator cullin-4B
(CUL4B) via p53 ubiquitination in stressed cells [245]. Moreover, ROS
promotes p53 acetylation and induction of premature senescence by
inhibition of the deacetylase SIRT1 in ﬁbroblasts [246]. In epithelial
cancer cells, the transcription factor FOXp3 accelerates p53-mediated
senescence while also increasing ROS levels and p21 expression,
demonstrating the intricate link between ROS and these pathways
[247]. It has also been suggested that ROS can induce senescence
through activation of the p16INK4a/pRB pathway by activating p38
MAPK and extracellular regulated protein kinase (Erk) [248], although
in extrinsically induced senescence models, the same pathway was
engaged [249].
While there is evidence of the regulatory role of ROS in the
p16INK4a/pRB and p53/p21 pathways that lead to senescence and
certain pathologies, much remains to be elucidated to fully understand
the implication of oxidative stress as both an eﬀector and aﬀected agent
in cellular senescence.
5. Summary
The complexity of the aging process and the drive to comprehend
its molecular underpinnings, steers focus towards approaches to
improve organismal healthspan and lifespan. Despite the transition
from cell-culture curiosity to a potential regulator of cancer and aging,
cellular senescence remains enigmatic and continues to raise a variety
of complex of questions. Oxidative stress plays a major role in several
pathways that lead to cellular senescence and the associated secretory
phenotype. Although initially intended to be a protective response to
oncogenic insult, cellular senescence induced by DNA-damaging agents
and ROS, can potentially elicit harmful eﬀects and can drive many age-
related diseases. While the ROS-driven SASP has proven to be
beneﬁcial in certain conditions, it is also associated with perpetuating
a pathological inﬂammatory state. The ability to genetically ablate
senescent cells has clearly established a causal role for senescence in
many degenerative disease processes, and while there is much un-
known with respect to the role of oxidative stress in such processes, the
evidence compiled here suggests that precise ROS-mitigation may limit
senescence and senescence-associated pathologies. However, transla-
tion of these ﬁndings into relevant human interventions is at present
restricted due to our incomplete understanding of both the basic
molecular biology of senescent cells in vivo and the etiology of
senescence-associated pathologies. While the long-standing notions
of the free radical theory of aging postulating a causal role of ROS in
the aging process (Harman, 1956) seem to ﬁt with several studies,
there are a number of observations that suggest that the cellular eﬀects
of ROS, with regard to inducing senescence, do not unequivocally
translate into organismal aging. Therefore, eﬀorts should be made to
escalate research directed at resolving the basic biology of cellular
aging and the redox-control of these mechanisms to generate inte-
grated therapeutic strategies to improve human health and lifespan.
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